Pulse Biosciences, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-24.7M | $-18.6M | $-17.4M | $-19.4M | $-19.2M | $-16.8M | $-19.4M | $-12.7M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $88.0K | $88.0K | $89.0K | $100.0K | $100.0K | $117.0K | $180.0K | $100.0K |
| Amortization | $166.0K | $167.0K | $166.0K | $166.0K | $167.0K | $166.0K | $166.0K | $167.0K |
| Stock-Based Compensation | $5.0M | $1.9M | $5.0M | $5.6M | $5.2M | $5.7M | $6.8M | $3.0M |
| Net Cash from Operating Activities | $-18.7M | $-14.6M | $-14.8M | $-13.0M | $-12.8M | $-13.5M | $-9.1M | $-9.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $90.0K | $33.0K | $105.0K | $62.0K | $103.0K | $45.0K | $53.0K | $38.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-90.0K | $-33.0K | $-105.0K | $-62.0K | $-123.0K | $-45.0K | $-53.0K | $-38.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $52.1M | $2.2M | $381.0K | $2.0M | $0 | $14.8M | $48.2M | $61.9M |
| Net Change in Cash | $33.3M | $-12.4M | $-14.5M | $-11.1M | $-12.9M | $1.2M | $39.0M | $52.8M |
| Free Cash Flow | $-18.8M | $-14.6M | $-14.9M | $-13.1M | $-12.9M | $-13.6M | $-9.2M | $-9.1M |